Sirona Biochem Corp.

VANCOUVER, BC -- (Marketwire) -- 12/08/09 -- Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity, announced today that its unique Sodium-Glucose Transport Inhibitor molecule has reached a critical developmental milestone. Sirona Biochem CEO, Dr. Howard Verrico, said, "Our unique Sodium-Glucose Transporter Inhibitor ('SGLT') molecule synthetic process is now ... read more

VANCOUVER, BC -- (Marketwire) -- 12/07/09 -- Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on drug development for diabetes and obesity, announced today the fourth major appointment this month to its Scientific Advisory Board, Professor B. Mario Pinto, one of Canada's leading chemical biologists. Professor Pinto is a pioneer in the ... read more

VANCOUVER, BC -- (Marketwire) -- 11/23/09 -- Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on drug development for diabetes and obesity, announced today another major appointment to its Scientific Advisory Board, Professor Bruce Verchere, one of Canada's leading diabetes scientists. Sirona Biochem CEO, Dr. Howard Verrico, said, "We consider ourselves very fortunate ... read more

VANCOUVER, BC -- (Marketwire) -- 11/17/09 -- Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity drug development, says the latest results from a clinical trial with a competitor's SGLT Inhibitor demonstrates the major opportunity for the company with its unique molecules. Sirona Biochem CEO, Dr. Howard Verrico, said, ... read more

VANCOUVER, BC -- (Marketwire) -- 11/12/09 -- Sirona Biochem Corp. (TSX-V: SBM) CEO, Dr. Howard Verrico, says the threat of diabetes for young Canadians is being vastly underestimated and will have profound consequences. Sirona Biochem CEO, Dr. Howard Verrico, said, "Diabetes and obesity are rampant. Children being born today in Canada have a ... read more

VANCOUVER, BC -- (Marketwire) -- 11/05/09 -- Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on drug development for diabetes and obesity, announced today the second major appointment this week to its Scientific Advisory Board, Professor Denis Richard, one of Canada's leading obesity scientists. Sirona Biochem CEO Dr. Howard Verrico said, "Professor ... read more

VANCOUVER, BC -- (Marketwire) -- 11/03/09 -- Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech drug development company focused on diabetes and obesity, announced today the appointment of Professor Michael Walker, PhD, one of Canada's leading biotech start-up company pioneers, to its Scientific Advisory Board. Sirona Biochem CEO Dr. Howard Verrico said, "Professor Walker ... read more

VANCOUVER, BC -- (Marketwire) -- 10/13/09 -- Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity, says a newly released Dutch diabetes research paper claims obesity alone may be the best predictor of undiagnosed diabetes. Sirona Biochem CEO, Dr. Howard Verrico, said, "This study by Radboud University Nijmegen Medical ... read more

VANCOUVER, BC -- (Marketwire) -- 09/29/09 -- Mark Senner, President, Reports: Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity, announced today the first major appointment to its Scientific Advisory Board, patent lawyer Jacques Warcoin, CEO of Cabinet Regimbeau in Paris, France. M. Warcoin filed the first biotechnology ... read more

VANCOUVER, BC -- (Marketwire) -- 09/22/09 -- Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity, announced today that it is accelerating its drug development program following a visit to its French partner TFChem's new lab. Mark Senner, President, who has just returned from TFChem's grand opening in Val ... read more

VANCOUVER, BC -- (Marketwire) -- 09/14/09 -- Mark Senner, President, Reports: Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity, says results of testing its unique SGLT inhibitor molecules demonstrate a key breakthrough milestone for Sirona Biochem. Sirona Biochem CEO, Dr. Howard Verrico, said, "There are two vital ... read more

VANCOUVER, BC -- (Marketwire) -- 08/27/09 -- Mark Senner, President, Reports: Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity, says critical testing of SGLT inhibitor molecules is proceeding as planned with 'positive indications.' Sirona Biochem CEO, Dr. Howard Verrico, said, "I can report to shareholders that we are ... read more

VANCOUVER, BC -- (Marketwire) -- 07/29/09 -- Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity, announced today that it has now taken delivery of its first batch of unique SGLT compounds from its French partner TFChem (Rouen, France) for screening and evaluation. "The successful production of these new ... read more

VANCOUVER, BC -- (Marketwire) -- 07/16/09 -- Sirona Biochem Corp. (TSX-V: SBM) announced today it is now ready to begin testing its novel new compounds to fight diabetes and obesity. The completion of the company's key SGLT biological assessment test and testing will be done under contract with Richmond, BC based SignalChem. Sirona Biochem ... read more

VANCOUVER, BC -- (Marketwire) -- 05/01/09 -- Further to its press release of April 20, 2009, Sirona Biochem Corp. (TSX-V: SBM) (TSX-V: HRD.P) (the "Company") announces today the final acceptance by the TSX Venture Exchange on May 4, 2009 of its Qualifying Transaction ("QT") with TFChem S.A.R.L. The Exchange also granted final ... read more